Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Safety and immunogenicity of two RNA-based covid-19 vaccine candidates
Edward E. Walsh
, Robert W. Frenck
, Ann R. Falsey
, Nicholas Kitchin
, Judith Absalon
, Alejandra Gurtman
, Stephen Lockhart
, Kathleen Neuzil
, Mark J. Mulligan
, Ruth Bailey
, Kena A. Swanson
, Ping Li
, Kenneth Koury
, Warren Kalina
, David Cooper
, Camila Fontes-Garfias
, Pei Yong Shi
, Özlem Türeci
, Kristin R. Tompkins
, Kirsten E. Lyke
Vanessa Raabe, Philip R. Dormitzer, Kathrin U. Jansen, Uğur Şahin, William C. Gruber
Show 5 others
Show less
Biochemistry & Molecular Biology
Research output
:
Contribution to journal
›
Article
›
peer-review
2030
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety and immunogenicity of two RNA-based covid-19 vaccine candidates'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Immunogenicity
100%
Vaccine Candidate
100%
RNA-based
100%
COVID-19 Vaccine
100%
BNT162b2
100%
Older Adults
87%
COVID-19
62%
United States
37%
Placebo
25%
Systemic Response
25%
Germany
25%
Geometric Mean Titer
25%
Phase 1 Trial
25%
Dose Effect
12%
Receptor-binding Domain
12%
Placebo-controlled
12%
Safety Assessment
12%
One-group
12%
Adverse Events
12%
RNA Vaccine
12%
One Dose
12%
Modified nucleosides
12%
Healthy Adults
12%
Dose Level
12%
Serum Samples
12%
2 Receptor
12%
Low Incidence
12%
Vaccine Dose
12%
Efficacy Evaluation
12%
Two-dose
12%
Convalescent Serum
12%
Local Reaction
12%
Dose Escalation
12%
Low Severity
12%
Lipid Nanoparticles
12%
Multiple Vaccine
12%
Modified RNA
12%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
12%
Prefusion Conformation
12%
State Support
12%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
100%
SARS Coronavirus
100%
Placebo
60%
Diseases
40%
Adverse Event
20%
Infection
20%
Receptor
20%
Normal Human
20%
Coronavirinae
20%
RNA Vaccine
20%
Group Trial
20%
Isoprenaline
20%
Nucleoside
20%
Solid Lipid Nanoparticle
20%